阅读说明：本技术 一种用于治疗肝硬化的中药混合物 (Traditional Chinese medicine mixture for treating liver cirrhosis ) 是由 丁赛丹 王剑 于贺 刘乐平 卢小爱 游瑞敏 于 2020-07-31 设计创作，主要内容包括：本发明公开了一种用于治疗肝硬化的中药混合物,包括α细辛醚、银杏内酯B、人参皂苷、表儿茶素以及冬凌草甲素。优点在于,本发明组合物各组分相互之间起到协同作用,显著改善肝硬化,其中,最佳药物配伍组为第四组即A1B1C1D1E2能够明显延缓肝硬化程度。(The invention discloses a traditional Chinese medicine mixture for treating liver cirrhosis, which comprises alpha asarone, ginkgolide B, ginsenoside, epicatechin and oridonin. The composition has the advantages that the components of the composition have a synergistic effect with each other, the liver cirrhosis is obviously improved, and the optimal medicine compatibility group is a fourth group, namely A1B1C1D1E2, so that the liver cirrhosis degree can be obviously delayed.)

1. A Chinese medicinal mixture for treating liver cirrhosis is characterized by comprising alpha asarone, bilobalide B, ginsenoside, epicatechin and oridonin.

2. The traditional Chinese medicine mixture for treating liver cirrhosis according to claim 1, wherein the contents of the components are 20-80 parts of alpha asarone, 15-60 parts of ginkgolide B, 10-40 parts of ginsenoside, 50-100 parts of epicatechin and 5-25 parts of oridonin.

3. The traditional Chinese medicine mixture for treating liver cirrhosis according to claim 2, which is characterized by comprising 20 parts of alpha asarone, 60 parts of ginkgolide B, 40 parts of ginsenoside, 100 parts of epicatechin and 25 parts of oridonin.

Technical Field

The invention belongs to the field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine mixture for treating liver cirrhosis.

Background

Cirrhosis is a progressive chronic liver disease characterized histologically by diffuse fibrosis of the cells of the liver tissue, pseudolobules and regenerating nodules, caused by one or more causes. A cascade of responses stimulates quiescent Hepatic Stellate Cells (HSCs) into an activated state, resulting in the accumulation of collagen and other extracellular matrix (ECM) components. Continued stimulation and accumulation of these substances can lead to destruction of liver structures and hepatic nerves, and reduce liver function, further causing liver fibrosis and development of cirrhosis.

Disclosure of Invention

In order to solve the problems, the invention provides a traditional Chinese medicine mixture for treating liver cirrhosis.

The purpose of the invention is realized by the following technical scheme: a Chinese medicinal composition for treating liver cirrhosis comprises alpha asarone, bilobalide B, ginsenoside, epicatechin and oridonin.

Further, the components comprise 20-80 parts of alpha asarone, 15-60 parts of ginkgolide B, 10-40 parts of ginsenoside, 50-100 parts of epicatechin and 5-25 parts of oridonin.

Further, 20 parts of alpha asarone, 60 parts of ginkgolide B, 40 parts of ginsenoside, 100 parts of epicatechin and 25 parts of oridonin.

The invention has the following beneficial effects:

1. the components of the composition of the invention have a synergistic effect with each other, and the liver cirrhosis is obviously improved.

2. The experimental data of the invention show that the regression or even reversion of the cirrhosis is possible, and support is provided for further research on treatment of cirrhosis in the future.

Drawings

FIG. 1 is a graph showing HE staining of liver tissue of mice in a normal group of liver cirrhosis.

FIG. 2 is a graph showing HE staining of liver tissue of mice in the liver cirrhosis model group.

FIG. 3 is a graph showing HE staining of liver tissue of mice in the liver cirrhosis treatment group.

FIG. 4 is a sirius red staining chart of liver tissue of mice in the normal group of liver cirrhosis.

FIG. 5 is a sirius red staining chart of liver tissue of mice in the liver cirrhosis model group.

FIG. 6 is a photograph showing the staining of sirius red in liver tissue of mice in the treatment group of liver cirrhosis.

Detailed Description

The technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to fig. 1 to 6 in the embodiments of the present invention, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all embodiments. The experimental procedures used in the following examples are all conventional procedures unless otherwise specified. Materials, reagents and the like used in the following examples are commercially available unless otherwise specified.

The bilobalide is an active ingredient in ginkgo, is a commonly used platelet activating factor receptor antagonist, and has certain protection effect on the central nervous system and the cardiovascular system. The alpha asarone is the extract of the traditional Chinese medicine grassleaf sweelflag rhizome, and the grassleaf sweelflag rhizome is the traditional Chinese medicine in China and has the function of treating mental and cardiovascular and cerebrovascular diseases. Alpha-asarone is reported to inhibit HMG-COA reductase and treat hyperlipidemia. Ginsenoside is an active ingredient in ginseng, has the effects of resisting inflammation and oxidation, and the like, and has a certain improvement effect on cognitive function and a certain cure effect on liver diseases through research in recent years.

Epicatechin is a natural plant flavanol compound, is mostly present in tea plants, is also an active ingredient of some common traditional Chinese medicines, and is how to fleece-flower root. Research shows that epicatechin has excellent neuroprotective effect and liver protecting capacity. Oridonin is a diterpenoid compound with antioxidant and antiinflammatory effects. Research shows that oridonin has excellent inhibiting effect on microglia inflammation activation in nervous system and direct inhibiting effect on NLRP3 and NF kappa B mediated inflammation passage.

The thioacetamide of the present invention was purchased from Cupu' er Biotech limited, Shanghai (batch: CAS: 62-55-5).

1. Moulding and grouping

A total of 60 ICR male mice (from the experimental animal center of the university of medical, wenzhou) weighed 18-20g, and the care and use mouse procedures in all experiments were in accordance with the claims of the ethical committee of the first hospital affiliated with the university of medical, wenzhou. Mice were divided into control, model, and treatment groups. Mice were injected intraperitoneally with Thioacetamide (TAA) (200 mg/kg/mouse) 2 times per week, administered for 11 weeks to induce cirrhosis, and the control group was injected with the same amount of physiological water.

2. Index measuring method

2.1 liver function assay

We obtained mice from each group after the last dose. Mice were bled from the eyeball by light ether anesthesia. Standing the blood for 30min, centrifuging at 5000r/min for 5 min, collecting serum, packaging, and storing at-80 deg.C. Detecting glutamic-oxaloacetic transaminase (AsT) and glutamic-pyruvic transaminase (ALT), and summarizing the results to SPSSl7.0 statistical software for data processing.

2.2 HE staining

The animals were sacrificed by exsanguination, livers were removed, fixed with 4% paraformaldehyde, dehydrated with ethanol, transparent with xylene, waxed, and finally embedded with wax with a melting point of 56 ℃ to make paraffin tissue. Dewaxing a conventional section (the thickness of the conventional section is 3.5 cm) to water, staining the conventional section with hematoxylin for 5-10 min, washing the conventional section with water, differentiating the conventional section with 1% hydrochloric acid alcohol for several seconds, turning blue, staining the conventional section with eosin for several seconds, dehydrating the conventional section, enabling xylene to be transparent, and sealing the conventional section with a neutral resin adhesive. The morphology of the tissue was observed under a microscope.

2.3 sirius dyeing

Making a paraffin section with the thickness of about 5 mu m on the liver tissue, and performing conventional dewaxing; placing the slices in celestite blue solution, and dyeing for 10 min; then putting the slices into sirius red-bitter acid liquor, and dyeing for 20 min; placing into hematoxylin staining solution, and staining for 10 min; washing hematoxylin with distilled water; dehydrated (absolute alcohol), clear (xylene), and mounted (neutral gum).

2.4 methods of administration and groupings

According to L₈(2⁷) The method comprises the steps of randomly combining 8 groups designed by an orthogonal design table, preparing α mixture solutions of asarone, bilobalide B, ginsenoside, epicatechin and oridonin in different proportions, determining dosage levels of 5 effective components according to literature search results, performing an orthogonal experiment of comprehensive analysis by using actual errors, determining the optimal curative effect proportion of 5 patients for preventing and treating hypomnesis of liver cirrhosis mice, performing index detection 4 weeks after administration, wherein the dosage levels of the 5 effective components are shown in a table 1, and the dosage levels of the 5 effective components are shown in a table 2.

Table 1. drug compatibility: concentration level (mg/kg/d)

TABLE 25 grouping of the effective component dosages (mg/kg/d)

3. Statistical analysis

Analysis was performed using spss.22 software and data are expressed in x ± s. The comparison of escape latencies of rats in the Morris water maze was performed by a one-way anova with repeated measures, and the comparisons between groups of the remaining variables were tested by student's t, with P <0.05 being statistically significant for the dissimilarity.

4. Results

4.1 detection results of liver function in liver-cirrhosis mice

After 8 weeks of modeling, ALT and AST of the mice in the model group are obviously increased compared with those in the blank group, and the difference has statistical significance (P is less than 0.05); after 8 drug groups intervene in the cirrhosis mice respectively, we find that the optimal drug compatibility group is the fourth group, namely A1B1C1D1E2, which can obviously delay the cirrhosis degree (P < 0.05).

4.2 hepatic cirrhosis mouse HE results

Mice showed: in the normal group of mice, the pathological manifestations of the liver are normal, and obvious conditions such as hepatocyte degeneration and necrosis, inflammatory cell infiltration and fibrous precipitation are not found. The hepatic lobules of the mice in the model group have structural disorder, the shapes of the hepatic cells are irregular, the clinical area and the hepatic lobules have obvious inflammatory cell infiltration, and the pathological changes are gradually aggravated along with the time and the structures of the clinical area are damaged. Pathological changes of the liver of the mice in the A1B1C1D1E2 group are obviously weaker than those of the mice in the model group, the liver shows that the shape of liver cells is normal and is arranged in sequence, the shape of cell nuclei is circular, cytoplasm is full, the sink area is infiltrated by a plurality of lymphocytes, no bile duct damage and liver lobule damage are caused, and the formation of fibrous intervals is not found. The results are shown in FIGS. 1 to 3.

4.3 results of sirius staining in cirrhosis mice

The sirius red and the lining dye solution thereof are strong acid dyes, are easy to combine with basic groups in collagen molecules, and are firmly adsorbed. The collagen fiber has positive uniaxial birefringence property by polarized light microscopy, and can enhance birefringence and improve resolution after being combined with sirius red dyeing liquid, thereby distinguishing two types of collagen fibers. Collagen Fiber (Collagen Fiber) is the most widely distributed Fiber in connective tissues and is widely distributed in various organs, among which skin, sclera and tendon are most abundant. The solvent of the sirius red staining solution is a liner staining PA saturated solution, and is mainly used for the research on the abnormal collagen fiber or the fiber proliferation in various tissue pathological changes, and the collagen fiber of tissues such as a tube and the like is stained red. As shown in the figure by 100-fold microscopic observation, compared with the control group, the liver collagen fibers of the MHE model group rats are remarkably increased, the collagen staining is obvious around the vascular region and on the wall of the lobular interlobular artery and vein, and the liver cirrhosis degree of the mice is remarkably delayed by the treatment group. The results are shown in FIGS. 4 to 6.

4.4 comparison of therapeutic effects in each treatment course

Group of	n	Time of treatment	Degree of cirrhosis
				Control group	6	4 weeks	Is normal
Model set	6	4 weeks	Weighting device
				Treatment group	6	4 weeks	Mitigation of

It will be evident to those skilled in the art that the invention is not limited to the details of the foregoing illustrative embodiments, and that the present invention may be embodied in other specific forms without departing from the spirit or essential attributes thereof, and it is therefore intended that the present embodiments be considered in all respects as illustrative and not restrictive, the scope of the invention being indicated by the appended claims rather than by the foregoing description, and all changes which come within the meaning and range of equivalency of the claims are therefore intended to be embraced therein.